Ipstyl Autogel

Lanreotide, the active ingredient in Ipstyl Autogel, is a somatostatin analog presented as a long‑acting injectable for subcutaneous use. It treats acromegaly and hormone‑secreting neuroendocrine tumors in adult patients.

GNH USA supplies Ipstyl Autogel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lanreotide is used to manage conditions driven by excess growth hormone or hormone secretion from neuroendocrine tumors.

Acromegaly: reduces serum IGF‑1 levels and controls tumor growth. Neuroendocrine tumors (carcinoid syndrome): alleviates flushing, diarrhea and other hormone‑related symptoms. Post‑surgical residual disease in acromegaly: maintains long‑term hormonal control.

Lanreotide may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Injection site pain or erythema - Nausea or vomiting - Diarrhea or abdominal cramps - Headache - Hyperglycemia or altered glucose tolerance - Fatigue

Serious or Rare Side Effects: - Gallstone formation or biliary colic - Acute pancreatitis - Severe allergic reactions (anaphylaxis, angioedema) - Cardiac arrhythmias - Severe hyperglycemia leading to ketoacidosis - Pituitary apoplexy (rare)

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for known safety concerns.

Monitor glucose: patients with diabetes may experience worsening glycemic control. Assess gallbladder: risk of gallstone development warrants periodic imaging. Screen for hypersensitivity: avoid use in individuals with known allergy to lanreotide or formulation excipients. Pregnancy: prescribe only when potential benefit justifies potential risk to the fetus. Renal or hepatic impairment: consider closer monitoring and possible dose adjustment. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medications that affect hormone levels or metabolic pathways.

Major Interactions (Avoid): - Co‑administration with other somatostatin analogues (e.g., octreotide) may amplify hormonal suppression and hyperglycemia. - Concomitant cyclosporine can increase lanreotide plasma concentrations. - Use with investigational agents that target the same receptors should be avoided.

Moderate Interactions (Monitor Closely): - Antidiabetic drugs (insulin, sulfonylureas) may require dose adjustments due to altered glucose homeostasis. - Warfarin: potential effect on coagulation parameters warrants INR monitoring. - Oral contraceptives: somatostatin analogues may reduce steroid hormone levels, affecting efficacy. - Antifungal azoles (e.g., ketoconazole) may modify lanreotide metabolism. - Beta‑blockers: monitor for additive effects on heart rate and blood pressure.